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1,4,5-trisphosphate (IP3) receptor and functions as an inhibitory regulator of this receptor. Unexpectedly, many
functions have subsequently been identiﬁed for IRBIT including the activation of multiple ion channels and ion
transporters, such as the Na+/HCO3− co-transporter NBCe1-B, the Na+/H+ exchanger NHE3, the Cl− channel
cystic ﬁbrosis transmembrane conductance regulator (CFTR), and the Cl−/HCO3− exchanger Slc26a6. The
characteristic serine-rich region in IRBIT plays a critical role in the functions of this protein. In this review, we
describe the evolution, domain structure, expression pattern, and physiological roles of IRBIT and discuss the
potential molecular mechanisms underlying the coordinated regulation of these diverse ion channels/
transporters through IRBIT. This article is part of a Special Issue entitled: Calcium signaling in health and disease.
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The precisely regulated ﬂow of ions into and out of cells and
organelles is essential for all living organisms. Three classes of proteins
move ions across membranes; ion channels, ion pumps and ion
transporters. Ion channels allow for the passive diffusion of ions down
their electrochemical gradients. Ion pumps actively transport ions
against their gradient by using the energy of ATP hydrolysis. Ion
transporters, such as ion cotransporters and ion exchangers, couple
downhill movements of ions to the uphill movements of other ions or
substances [1–3]. Among the ions passing through these membrane
transport proteins, Ca2+ plays a unique role as a universal second
messenger. Increases in intracellular Ca2+ concentration induced
through theopening of Ca2+ channels located on plasmaor intracellular
membranes regulate the functions of numerous proteins [4]. Inositol
1,4,5-trisphosphate (IP3) receptors (IP3Rs) are IP3-gated Ca2+ channels
located on the intracellular Ca2+ storage organelles, and these receptors
play important roles in the regulation of various cellular processes,
including fertilization, development, secretion, gene expression,
synaptic plasticity, and cell death [5–7].
IRBIT (IP3R binding protein releasedwith inositol 1,4,5-trisphosphate)
(also called AHCYL1 or DCAL) was identiﬁed as an IP3R-binding protein
[8]. IRBIT suppresses IP3R activation through competition with IP3 for
the common binding site on IP3R [9]. Unexpectedly, studies have
shown that IRBIT also regulates other ion channels and ion transporters,
such as the Na+/HCO3− co-transporter NBCe1-B [10], the Na+/H+signaling in health and disease.
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ights reserved.exchanger NHE3 [11], the Cl− channel CFTR (cystic ﬁbrosis transmem-
brane conductance regulator) [12], and the Cl−/HCO3− exchanger
Slc26a6 [13]. Thus, IRBIT is a regulator of both ion channels and ion trans-
porters. In this review, we describe the evolution, structure, expression,
target proteins, and physiological roles of IRBIT, and discuss the molecu-
lar mechanisms underlying the regulation of these diverse ion channels/
transporters through IRBIT.
2. Conservation among species
IRBIT and its homolog Long-IRBIT (also called AHCYL2) constitute
the IRBIT family [14]. A large portion of the C-terminal region of IRBIT
family proteins shows ~50% homology with the ubiquitous housekeep-
ing enzyme S-adenosyl-L-homocysteine hydrolase (AHCY) [8,15,16]
(Fig. 1). AHCY regulates the level of intracellular transmethylation
reactions by catalyzing the reversible hydrolysis of S-adenosyl-L-
homocysteine (SAH) to adenosine and L-homocysteine. AHCY main-
tains low cellular concentrations of SAH, a product inhibitor of
methyltransfer reactions from the methyl donor S-adenosyl-L-
methionine to biological acceptors, such as DNA, RNA and proteins
[17,18]. AHCY has been identiﬁed in all organisms from bacteria to
humans, whereas the IRBIT family is present in vertebrates and insects
but not in nematodes, yeast, prokaryotes, and plants, suggesting that
the IRBIT family forms an evolutionarily distinct family of molecules
[19]. A sequence derived from the duplication of an ancestral AHCY
gene is assumed to have acquired a different function required in higher
organisms in the course of evolution [20,21]. IRBIT is highly conserved
among species, and the human andmouse orthologs have 100% protein
identity, suggesting an important function for this protein [8]. Alter-
native splicing variants with different N-termini have been reported
for human and zebraﬁsh IRBIT [19] (Fig. 1). In this review, we refer to
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Fig. 1. Structure of the IRBIT family in humans (h), mice (m), zebraﬁsh (z), and Drosophila (d). The LISN domain, the PP1 binding site (PP), the serine-rich region (SER), the coiled-coil
domain (CC), and the AHCY domain are indicated. The coiled-coil domain in Drosophila IRBIT homologs (CG9977 and Ahcy89E) is obscure.
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IRBIT homologs, Ahcy89E and CG9977, have been reported [19,20,22].
Both proteins show 67–74% homology with human IRBIT and Long-
IRBIT. However, neither of these homologs has the Long-IRBIT-speciﬁc
N-terminal domain (LISN domain), suggesting these proteins are more
closely related to IRBIT than to Long-IRBIT (Fig. 1).
3. Structure
Fig. 1 shows the structure of the IRBIT family. The IRBIT family
comprises a C-terminal AHCY domain with homology to AHCY and an
N-terminal extension containing a serine-rich region with multiple
phosphorylation sites [8,15]. Long-IRBIT, but not IRBIT, has an additional
N-terminal appendage, termed the LISN domain [14] (Fig. 1).
3.1. The AHCY domain
Although the AHCY domain (residues 105–530 in mouse IRBIT) of
IRBIT shows homology to AHCY, IRBIT does not exhibit the same
enzyme activity as AHCY, probably reﬂecting the substitution of amino
acids important for substrate binding [8,15]. AHCY requires NAD+ as a
cofactor for the enzyme function [17]. The NAD+ binding motif of
AHCY is conserved in IRBIT [8,15], and recombinant IRBIT expressed in
Escherichia coli binds to NAD+ [23], although the role of NAD+ in IRBIT
function remains unknown. The AHCY domain of the IRBIT family con-
tains a coiled-coil domain (Fig. 1), involved in the interaction with IP3R
[8], and the activation of CFTR and Slc26a6 [12,13]. The last 10 C-
terminal amino acids of IRBIT also play a role in the interaction with
IP3R [24] and the activation of CFTR [12]. The C-terminal sequence
YYRY–COOH of the IRBIT family is proposed to be a class-II PDZ-ligand
[24,25]. However, this sequence does not ﬁt the classical class-II PDZ-
ligand motif (X–ψ–X–ψ–COOH, where X is any residue and ψ is a hydro-
phobic amino acid [26,27]), andno PDZdomain-containing proteins have
been reported to bind IRBIT. Whether the C-terminus of the IRBIT family
actually functions as a PDZ ligand needs future experimental validation.
Mammalian AHCY forms a tetramer [28,29]. Similarly, IRBIT and
Long-IRBIT form homomultimers via the AHCY domain. In addition,
IRBIT and Long-IRBIT form heteromultimers with each other. The
AHCY domain is necessary and sufﬁcient for multimerization [9,14].
Gomi et al. used gel ﬁltration to demonstrate that recombinant IRBITexpressed in E. coli forms trimers, but chemical cross-linking experi-
ments showed dimer formation [23]. Notably, an accurate number of
subunits per molecule have not been conﬁrmed yet.3.2. The serine-rich region and its phosphorylation
Only ~100 amino acids of the N-terminal extension confer IRBIT
with novel functions distinct from AHCY. This region contains a
serine-rich region (residues 62–103 in mouse IRBIT) (also deﬁned as a
PEST domain [24]), which is well conserved among the IRBIT family
[8] (Figs. 1 and 2). Sixteen Ser residues are clustered in the serine-rich
region of IRBIT. Multiple Ser/Thr residues, including Ser68, Ser71,
Ser74, Ser77, Thr82, Ser84, and Ser85, highly conserved fromDrosophila
to humans, in the serine-rich region of IRBIT are phosphorylated [9,30]
(Fig. 2). Among these, Ser68 is one of the most functionally important
phosphorylation sites. Indeed, Ser68 mutations abolish the ability of
IRBIT to interact with and/or regulate target proteins, including IP3R
[9], NBCe1-B [10], NHE3 [31], CFTR [12], and Fip1 [32]. Ser68 ﬁts the
consensus phosphorylation motif of kinases belonging to Ca2+/
calmodulin-dependent protein kinase (CaMK) family [33–35]. In vitro
kinase assays have shown that IRBIT is phosphorylated by CaMKIV or
protein kinase D (PKD) [9,36]. Once Ser68 is phosphorylated, Ser71
becomes a potential phosphorylation site for casein kinase I (CKI),
which requires a priming phosphate located three amino acids up-
streamof the target Ser/Thr [34,37]. Phosphorylation of Ser71 generates
subsequent potential CKI phosphorylation sites at Ser74, Ser77, and
Ser80 (Fig. 2). CKI phosphorylates IRBIT in vitro in a phosphorylated-
Ser68-dependent manner [9,36], and mass spectrometry analysis
showed that CKI phosphorylates Ser71 and Ser74 [36]. Inhibition of
CKI decreases phosphorylation of IRBIT in intact cells [9]. These observa-
tions indicate that Ser68 is themaster phosphorylation site, and priming
phosphorylation at Ser68 induces the sequential phosphorylation, at
least at Ser71 and Ser74, by CKI. The kinases that phosphorylate Ser68
in vivo remain unknown; however, CaMKII is a potential candidate
[31]. Ser68 is dephosphorylated by protein phosphatase-1 (PP1) [36].
Regulation of the phosphorylation status of Ser68 through kinases and
phosphatases determines the activity of IRBIT. In addition, two-step
phosphorylation: Ser68 by CaMK family kinases and Ser71/74 by CKI,
may allow elaborate control of IRBIT activity (see below). Proteomic
analysis of phosphorylated proteins in synaptic fractions revealed that
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Fig. 2. Sequence alignment of the PP1 binding site and the serine-rich region of the IRBIT family. Identical residues are highlighted in yellow. The in vitro CaMKIV/PKD phosphorylation site
(Ser68 in mouse IRBIT) is indicated by a red circle. CKI phosphorylation sites (Ser71 and Ser74 in mouse IRBIT) are indicated by black squares. Potential CKI phosphorylation sites (Ser77
and Ser80 in mouse IRBIT) are indicated by gray squares. Phosphorylation sites in mouse synaptic fractions (Thr82, Ser84, and Ser85) are indicated by stars.
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[30] (Fig. 2); however, kinases responsible for the phosphorylation and
their functional signiﬁcance remain unknown.
The serine-rich region is subject to proteolytic degradation aswell as
phosphorylation. IRBIT is cleaved between Asp73 and Ser74, which
results in the loss of binding ability to IP3R [24]. Proteases responsible
for this cleavage have not been identiﬁed; however, Devogelaere et al.
speculate that a calcium-dependent protease, calpain, might be a
potential candidate based on the amino acid sequence of the serine-
rich region of IRBIT [25].
3.3. The protein phosphatase-1 binding site
A consensus PP1 docking site, R/K-X0–1-I/V-{P}-F (where {P} denotes
any residue except proline), is located near the serine-rich region
(residues 40–44 in mouse IRBIT), which mediates interaction of PP1 to
IRBIT [36] (Figs. 1 and 2). PP1 dephosphorylates Ser68 of IRBIT and
inhibits subsequent phosphorylation by CKI [36]. Mutant IRBIT lacking
the PP1 binding site shows higher afﬁnity to IP3R [36] and higher
stimulatory ability to NBCe1-B [38], probably reﬂecting the hyper-
phosphorylation of IRBIT. Conversely, mutations to the strong con-
sensus PP1 binding site (RRVRF) abolish the stimulatory capacity of
IRBIT toward NBCe1-B [38]. These results support the idea that the
phosphorylation status of Ser68 determines the activity of IRBIT.
IRBIT functions as a scaffold protein, which recruits PP1 to ion trans-
porters, such as NBCe1-B, CFTR and Slc26a6. PP1 bound to the PP1
docking site on IRBIT dephosphorylates ion transporters and facilitates
the expression of these proteins on cell surface [13,39,40].
Human IRBIT has an alternative splicing variant, IRBIT-B,which lacks
the ﬁrst N-terminal 47 amino acids, including the PP1 binding site [19]
(Figs. 1 and 2). Thus, human IRBIT-B is expected to be more resistant to
dephosphorylation by PP1 and lose the ability to regulate the cell
surface expression of ion transporters. The PP1 binding site is conserved
in Long-IRBIT, but not in Drosophila IRBIT homologs (Figs. 1 and 2).
3.4. The LISN domain
Long-IRBIT, but not IRBIT, has a unique N-terminal appendage
(amino acid residues 1–109 in human Long-IRBIT), termed the LISN do-
main (Long-IRBIT speciﬁc N-terminal domain). The LISN domain is con-
served only in vertebrates, but not in Drosophila (Fig. 1). The LISN
domain is rich in Ala and Pro and has no homology with reported pro-
teins. Despite high homology with IRBIT (~88% amino acid identity),
Long-IRBIT does not bind to IP3R. Deletion mutagenesis revealed that
the LISNdomain inhibits the interactionwith IP3R [14]. Themechanisms
bywhich the LISN domain suppresses the interaction remain unclear. At
least the LISNdomain does not interferewith thephosphorylation of Ser
residues in the serine-rich region of Long-IRBIT corresponding to Ser68/
71/74/77 of IRBIT [14]. Steric hindrance or masking of the critical
phospho-serines might be possible mechanisms by which the LISN
domain exerts its inhibitory effect.4. Expression
4.1. Tissue and cell type distribution
IRBIT is ubiquitously expressed in adult mouse tissues. The IRBIT
protein is most abundant in the brain and relatively high expression
has been observed in the testis, ovary, thymus, spleen, kidney and
lungs, while low expression has been detected in the heart and liver
[8]. Immunohistochemistry in the mouse brain showed that IRBIT is
highly expressed in the cerebellum and hippocampus ([14] and unpub-
lished observations). In the cerebellum, IRBIT is expressed in neurons,
but the most abundant expression of this protein has been detected in
glial cells in molecular layers [14]. IRBIT is also expressed in the sympa-
thetic neurons of the rat superior cervical ganglion [41]. In the rat kid-
ney, IRBIT is expressed in the proximal convoluted tubules and outer
medulla [31]. IRBIT is also expressed in the apical pole of themouse pan-
creatic duct where it colocalizes with IP3R2 and CFTR [12] and bovine
parotid acinar cells where it colocalizes with NBCe1-B [42]. In human
peripheral blood leukocytes, IRBITmRNA is speciﬁcally detected in den-
dritic cells, but not in monocytes, T and B lymphocytes, natural killer
cells, and granulocytes [15]. In chickens, IRBIT mRNA is detected in the
testis, oviduct (but not the ovary), kidney, liver, and gizzard, whereas
little expression is observed in the brain, heart, and muscle. In situ hy-
bridization and immunohistochemistry have shown that IRBIT is abun-
dant in the luminal and glandular epithelia in the chicken oviduct [43].
The expression of Long-IRBIT inmice is high in the brain and kidney,
intermediate in the thymus, spleen, testis and ovary, low in the lungs
and liver, and not detected in the heart. Long-IRBIT protein expression
is much lower than that of IRBIT in all tissues examined. Immunohisto-
chemistry of mouse brain showed that Long-IRBIT and IRBIT are highly
expressed inmolecular layers in the cerebellum. However, in contrast to
IRBIT, Long-IRBIT expression ismost abundant in interneurons, suggest-
ing the cell-type speciﬁc functions of these proteins in the brain [14].4.2. Induction during differentiation and development
Expression of IRBIT can be regulated through cell differentiation
and/or extracellular stimuli. IRBIT expression is up-regulated through
the activation and differentiation of human dendritic cells. IRBIT
mRNA expression is low in freshly isolated monocytes and markedly
induced when these cells are differentiated into monocyte-derived
dendritic cells, mediated through the cytokines GM-CSF and IL-4 [15].
The signaling cascades leading to IRBIT induction remains largely
unknown; however, Jeong et al. reported that the up-regulation of
IRBIT by estrogen agonists depends on the mitogen-activated protein
kinase (MAPK) signaling cascade in chicken oviduct epithelial cells [43].
In zebraﬁsh, IRBIT mRNA expression drastically changes during
development. At the shield stage of embryos, IRBIT expression is low
and steadily increased until the 25-somite stage. At 25 h post-
fertilization, IRBIT expression is markedly reduced to half that of the
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embryogenesis in zebraﬁsh [19].
4.3. Subcellular localization
Biochemical fractionation of the mouse cerebellum showed that
IRBIT is present in both cytosolic andmembrane fractions. IRBITwas ex-
tracted from the membrane fraction using high salt buffer, indicating
that IRBIT is a peripherally membrane-bound protein [8]. This observa-
tion is consistent with the fact that most IRBIT-interacting proteins are
membrane-integrated proteins. Interestingly, IRBIT is more phosphory-
lated in the membrane fraction than in the cytosolic fraction [14]. Be-
cause the phosphorylation of IRBIT facilitates its association with
transmembrane binding partners, such as IP3R [8,9], and NBCe1-B
[10], this observation suggests that the phosphorylation status of IRBIT
regulates the subcellular localization of this protein via interactions
with target proteins.
In most cultured cells, IRBIT is localized primarily in the cytoplasm
with little signal in the nucleus [8,32], and IRBIT is targeted to the endo-
plasmic reticulum (ER) through interactionswith IP3R [8] or the plasma
membrane through interactions with NHE3 [11]. However, in a human
ovarian epithelial cancer cell line, OVCAR-3, and primary chicken ovar-
ian cancer cells, IRBIT is predominantly localized in the nucleus [44],
suggesting that under some circumstances IRBIT translocates to the
nucleus. Indeed, a small fraction of IRBIT translocates from the cytosol
to the nucleus in response to oxidative stress in HEK293 cells [32].
Because deletion of the N-terminal domain, including the serine-rich
region of IRBIT, results in the distribution of IRBIT to the nucleus [8],
Devogelaere et al. proposed a model in which the proteolytic cleavage
or dephosphorylation of the serine-rich regionmight induce the nuclear
translocation of IRBIT [25]. Further studies on cleavage and phosphory-
lation status of nuclear IRBIT in ovarian cancer cells might validate this
model.
5. Regulation of target proteins
5.1. IP3R
IP3Rs are Ca2+ release channels located on intracellular Ca2+ storage
organelles, such as ER. IP3Rs are activated through binding to IP3, a sec-
ond messenger produced from the hydrolysis of phosphatidylinositol
4,5-bisphosphate (PIP2) by phospholipase C (PLC) in response to the
activation of cell surface receptors. Three subtypes of IP3Rs have been
identiﬁed in mammals, IP3R1, IP3R2, and IP3R3. IP3R1 is ubiquitously
expressed in various tissues, but is most abundant in the brain. IP3Rs
contain an IP3-binding domain near the N-terminus, a channel-
forming domain near the C-terminus, and a coupling domain separating
these two domains. IP3Rs play roles in numerous processes, including
fertilization, development, secretion, gene expression, synaptic plastici-
ty, and cell death [5–7].
Screening of IP3R1-associating proteins through afﬁnity puriﬁcation
using an IP3R1-conjugated column identiﬁed IRBIT from the rat
cerebellum [8]. IRBIT binds to all three subtypes of IP3Rs. IRBIT (IP3R
binding protein released with inositol 1,4,5-trisphosphate) was
so named because this protein is eluted from the IP3R1-conjugated
column upon the addition of IP3. IP3 dissociates IRBIT from IP3R1 with
an EC50 ~ 0.5 μM, a value within the physiological IP3 concentration
range [8]. A saturating dose of agonist stimulation, which produces a
high concentration of IP3, disrupts the interaction between IRBIT and
IP3R in intact cells [13]. Conversely, IRBIT efﬁciently suppresses IP3 bind-
ing to IP3R1 [9,24]. Scatchard analysis showed that IRBIT decreases the
afﬁnity of IP3R1 for IP3 approximately 14-fold [9]. In addition, IRBIT
binds to the IP3 binding domain (residues 224–604) of IP3R1 [8].
These ﬁndings indicate that IRBIT and IP3 competitively bind to the
same region of IP3R1 [9]. The results of a Ca2+ release assay using
cerebellar microsomes or permeabilized cells showed that IRBITsuppresses the IP3-induced Ca2+ release (IICR) in response to low, but
not saturating, concentrations of IP3 [9,24]. IRBIT increases the EC50 of
IP3 for IICR approximately sixfold [24]. Calcium imaging using intact
HeLa cells showed that siRNA knockdown of IRBIT or the overexpres-
sion of dominant-negative mutant IRBIT-S68A sensitizes IP3R to activa-
tion with a threshold dose of agonist stimulation [9]. Thus, IRBIT
prevents the activation of IP3R through the inhibition of the access of
IP3 to IP3R when the IP3 concentration is low.When agonist stimulation
results in high concentrations of IP3, IP3 displaces IRBIT and activates
IP3R. Direct competition of IRBIT with IP3 for the common binding re-
gion on IP3R regulates the threshold IP3 concentration required for the
activation of IP3R [9] (Fig. 3A, B). This mechanism is utilized to provide
signaling speciﬁcity in neurons. In rat sympathetic neurons, M1 musca-
rinic receptor agonist does not elicit IICR, whereas B2 bradykinin and
P2Y purinergic receptor agonists induce robust IICR. Interestingly, over-
expression of IRBIT-S68A greatly increases IICR induced throughmusca-
rinic receptors. Overexpression of wild-type IRBIT decreases IICR
through B2 bradykinin and P2Y purinergic receptors. These results re-
ﬂect the spatial coupling of IP3R and IP3 production sites. Stimulation
of muscarinic receptors is ineffective in producing IICR because IP3 is
produced too far from IP3R. Thus, the IP3 concentration at the IP3R is
too low to overcome the IRBIT threshold. Bradykinin and purinergic re-
ceptors produce robust IICR due to their spatial co-localization with
IP3R, where the IP3 concentration is sufﬁciently high to displace IRBIT
[41].
Phosphorylation of IRBIT regulates its afﬁnity to IP3R. As described
above, Ser68 in IRBIT is phosphorylated by kinases belonging to the
CaMK family, subsequently becoming a priming site for the sequential
phosphorylation of Ser71 and Ser74 by CKI [9,36]. In addition, Ser68 is
subject to dephosphorylation by PP1 [36]. Mutations at Ser68, Ser71,
or Ser74 dramatically reduce the afﬁnity of IRBIT for IP3R1. The IRBIT-
S68A mutant cannot suppress IP3 binding to IP3R1, and overexpression
of IRBIT-S68A enhances the IP3 sensitivity of IP3R in a dominant-
negative manner through multimerization with endogenous IRBIT [9].
Thus, Ser68 is a major phosphorylation site that plays a critical role in
the regulation of IP3R [9,36]. However, once Ser71 and Ser74 are phos-
phorylated by CKI, the dephosphorylation of Ser68 by PP1 does not af-
fect the inhibitory activity of IRBIT toward IP3R1, indicating that
phospho-Ser71/74, but not phospho-Ser68, is directly involved in the
suppression of IP3R [36]. The Ca2+-dependent phosphorylation of
IRBIT at Ser68 might function as a negative feedback regulation of IP3R
[31].
Binding determinants in IP3R are revealed by mutagenesis analy-
sis of the IP3-binding domain of IP3R1 [9]. The crystal structure of the
IP3-binding domain revealed two subdomains, the β-domain and the
α-domain, and showed that IP3 binds to a highly positively charged
pocket at the interface between these two subdomains [45]. Basic
amino acids such as Arg and Lys, located at the interface between
these two domains, are required for IP3 binding via interactions
with the phosphoryl groups of IP3 [45,46]. Interestingly, 10 of the
12 key amino acids are involved in the interaction with IRBIT as
well as IP3. Thus, IRBIT and IP3 recognize common basic amino
acids in the IP3-binding domain of IP3R1. These ﬁndings suggest
that a portion of the phosphorylated IRBIT might simulate the phos-
phate groups of IP3 to bind to the IP3-recognizing pocket of IP3R.
Thus, IRBIT might function as a “pseudoligand” of IP3R that competes
with the active ligand IP3 [9].
In contrast to IRBIT, Long-IRBIT hardly interacts with IP3R1,
despite high homology with IRBIT (~88% identity) and the complete
conservation of the amino acids essential for IP3R binding (Fig. 2).
The presence of the LISN domain in Long-IRBIT inhibits the interaction
with IP3R1. Long-IRBIT forms a heteromultimer with IRBIT via the
AHCY domain. The heteromultimer of IRBIT and Long-IRBIT weakly
interacts with IP3R1, indicating that the composition of IRBIT and
Long-IRBIT in the heteromultimer might determine the binding afﬁnity
for IP3R [14].
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Fig. 3.Models of IRBIT functions. (A) At resting state, or when the IP3 concentration near IP3R is low, phosphorylated IRBIT suppresses the activation of IP3R as an inhibitory gatekeeper
(left). When stimulation produces high concentrations of IP3, IP3 displaces IRBIT and activates IP3R. Active IRBIT released from IP3R binds to NBCe1-B and CFTR and increases the activities
(right). (B) At resting state,WKN/SPAK kinases phosphorylate NBCe1-B, CFTR, and Scl26a6 and sequester these proteins in intracellular vesicles (left). After stimulation, PP1, recruited by
IRBIT, dephosphorylates these proteins and induces their surface expression (right). (C) At resting state, unphosphorylated IRBIT does not bind to target proteins (left). IICR activates
CaMKII, and IRBIT is phosphorylated downstream of CaMKII. Phosphorylated IRBIT interacts with NHE3 and stimulates its surface expression. Phosphorylated IRBIT might bind to IP3R
to suppress its activity (right).
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IRBIT interacts with IP3R in the resting state and is dissociated from
IP3R when IP3 production is induced through extracellular stimuli,
suggesting that the IRBIT released from IP3R has different functions.
We screened IRBIT-binding proteins through co-immunoprecipitation
from mouse cerebellar extracts and identiﬁed pancreas-type Na+/
HCO3− cotransporter 1 (pNBC1/NBCe1-B) [10]. NBCe1 is an ion trans-
porter that mediates the movement of Na+ and HCO3− ions across the
plasma membrane. NBCe1 is encoded by the SLC4A4 gene and has
three splicing variants, kidney-type (kNBC1/NBCe1-A), pancreas-type
(pNBC1/NBCe1-B) and brain-type (bNBC1/NBCe1-C) [47–49]. The N-
terminal 85 amino acids of NBCe1-B/C replace the N-terminal 41
amino acids of NBCe1-A [50]. NBCe1-B is widely expressed in several
tissues, including the pancreas, prostate, colon, thyroid, spinal cord,
brain, and eye, whereas NBCe1-A is speciﬁcally expressed in the kidney
and NBCe1-C is expressed primarily in the brain. In secretory epitheliasuch as pancreatic ducts, NBCe1-B is localized at the basolateral
membrane, where it mediates HCO3− uptake and thereby contributes
to HCO3− secretion into the lumen. In non-epithelial cells, NBCe1-B
contributes to intracellular pH regulation by moving alkali into cells in
response to acid loads [47–49].
IRBIT speciﬁcally binds to NBCe1-B and not to NBCe1-A. IRBIT inter-
acts with the NBCe1-B/C-speciﬁc N-terminal 85-amino acid module,
which is different from the N-terminal region of NBCe1-A [10]. Electro-
physiological analysis in Xenopus oocytes revealed that IRBIT enhanced
NBCe1-B, but not NBCe1-A, transporter activity approximately seven-
fold, without affecting the cell surface expression of this transporter
[10,38]. Intracellular pH imaging conﬁrmed that IRBIT activates
NBCe1-B in mammalian cells. Moreover, IRBIT increases native NBCe1-
B activity in the mouse pancreatic duct [12,39]. Mutations at Ser68,
Ser71, Ser74, or Ser77 in the serine-rich region of IRBIT disrupt interac-
tions with NBCe1-B and the ability to activate NBCe1-B, suggesting that
the phosphorylation of these Ser residues is essential for the stimulatory
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dephosphorylates Ser68 [36]. Interestingly, mutating the PP1 binding
motif to the weak PP1 binding site (KQAQA) results in higher stimula-
tion of NBCe1-B by the mutant IRBIT compared with wild-type IRBIT,
and conversely, mutating the PP1 bindingmotif to the strong consensus
PP1 binding site (RRVRF) abolishes the activity of IRBIT in Xenopus oo-
cytes [38]. These results indicate that the phosphorylation status of
Ser68 (and concomitant Ser71 and Ser74) determines the stimulatory
activity of IRBIT to NBCe1-B.
The NBCe1-B/C-speciﬁc 85 amino acid N-terminal extension con-
tains an auto-inhibitory domain (AID), which suppresses the basal ac-
tivity of NBCe1-B/C [51]. Deletion mutagenesis revealed the AID
within residues 17–85 of NBCe1-B [38]. Because the IRBIT binding site
is located within residues 1–62 of NBCe1-B [10], the AID and the IRBIT
binding site largely overlap. Therefore, the mechanism of action of
IRBIT on NBCe1-B is partly assumed to mask the AID, thereby relieving
transporter autoinhibition [10,38]. In addition to direct activation,
IRBIT regulates the cell surface expression of NBCe1-B. The cell surface
expression of NBCe1-B is inhibited through the with-no-lysine (WNK)
kinases and Ste20-related proline alanine-rich kinase (SPAK) pathways
[52]. The WNK kinases recruit SPAK to NBCe1-B, and SPAK phosphory-
latesNBCe1-B, resulting in the internalization of NBCe1-B from the plas-
mamembrane [39,53]. Conversely, IRBIT recruits PP1 via its PP1 binding
site to NBCe1-B. PP1 complexes with IRBIT and dephosphorylates
NBCe1-B, restoring its cell surface expression [39]. Therefore, IRBIT reg-
ulates the activity of NBCe1-B through two independent mechanisms.
IRBIT directly activates NBCe1-B by relieving autoinhibition, and IRBIT
antagonizes the effect of theWNK/SPAK kinases to stabilize the expres-
sion of NBCe1-B at the plasmamembrane in cells expressingWNK/SPAK
kinases [40] (Fig. 3A, B). PP1 has dual functions on NBCe1-B: negative
regulation through the dephosphorylation of Ser68 in IRBIT [36,38]
and positive regulation through the dephosphorylation of NBCe1-B
[39,53]. Two-step phosphorylation of IRBIT: on Ser68 by CaMK family
kinases and on Ser71/74 by CKI, might enable the elaborate regulation
by PP1. That is, when IRBIT recruits PP1 to NBCe1-B, Ser68 on IRBIT
might also be dephosphorylated by PP1. However, it might not affect
the interaction with NBCe1-B once Ser71 and Ser74 are phosphorylated
by CKI, if the interaction is by the same mechanism as for IP3R [36].
NBCe1 belongs to the Na+-coupled HCO3− transporter superfamily,
comprising electrogenic Na+/HCO3− cotransporters (NBCe1 and
NBCe2), electroneutral Na+/HCO3− cotransporters (NBCn1 and
NBCn2), and a Na+-dependent Cl−/HCO3− exchanger (NDCBE), each
having multiple splicing variants [48,54]. NBCe1-B/C, NBCn1, NBCn2,
and NDCBE have conserved N-terminal AID and IRBIT-binding domains,
suggesting that these transporters are regulated by IRBIT. Indeed,
NBCn1-A, NBCn1-B, NBCn2-B, and NDCBE-B are activated by IRBIT
[53,54].
5.3. NHE3
NHE3 is a member of the Na+/H+ exchanger gene family (SLC9
family) and is expressed most abundantly in the kidney and intestine.
In the kidney, NHE3 is localized at the apical membrane of epithelial
cells in the proximal tubules and is responsible for Na+ and HCO3−
reabsorption. In the intestine, NHE3 contributes to basalNa+ absorption
via coupling to a Cl−/HCO3− exchanger. NHE3 continually cycles
between an intracellular juxtanuclear location and the plasma mem-
brane. Structurally, NHE3 comprises an N-terminal domain, which is
responsible for the Na+/H+ exchange, and a C-terminal cytoplasmic
domain, which modulates the transporter activity and regulates the
intracellular trafﬁcking of NHE3 [55,56].
He et al. performed yeast-two hybrid screening of NHE3-binding
proteins from a kidney library using the C-terminal cytoplasmic domain
as a bait and identiﬁed IRBIT [11]. IRBIT co-localizes with NHE3 in
rat renal proximal tubules [31]. In PS120 hamster ﬁbroblast cells
stably expressing NHE3, the overexpression of IRBIT results in theCa2+-dependent stimulation of NHE3 activity, and siRNA knockdown
of IRBIT attenuates NHE3 activity. The activation of NHE3 through
IRBIT is dependent on the IRBIT-binding domain in the C-terminal cyto-
plasmic domain of NHE3. IRBIT regulates NHE3 activity by facilitating
the cell surface expression of this transporter in a Ca2+- and CaMKII-
dependent manner [11]. Angiotensin II, which regulates ﬂuid reabsorp-
tion in renal proximal tubules, stimulates NHE3 activity in opossum
kidney proximal tubule (OKP) cells. IRBIT facilitates angiotensin II-
mediated activation of NHE3 in OKP cells. Angiotensin II stimulation
transiently enhances the interaction of IRBIT and NHE3, and mutating
Ser68 in IRBIT abolishes this interaction. Angiotensin II promotes the
cell surface expression of NHE3 in a Ca2+- and CaMKII-dependent
manner. These observations indicate that Ca2+ transients induced
through angiotensin II activate CaMKII, and CaMKII enhances the inter-
action of IRBIT with NHE3 through either the direct or indirect phos-
phorylation of Ser68 in IRBIT, resulting in the cell surface expression of
NHE3 [31] (Fig. 3C). In a human submandibular duct cell line (HSG
cells), IRBIT binds to NHE3, but not to NHE1 and NHE2. IRBIT enhances
NHE3-mediated intracellular pH recovery in response to cell acidiﬁca-
tion by promoting the cell surface expression of NHE3 [57]. NHE3 is
also expressed in the luminal membrane of the pancreatic and salivary
ducts, and might salvage HCO3− by secreting H+ into the duct lumen.
H+ then interacts with luminal HCO3− to generate CO2 at the resting
state. IRBIT might mediate HCO3− salvage through the regulation of
NHE3, when HCO3− secretion is not required [58,59].
5.4. CFTR
CFTR is a cAMP-activated Cl− channel identiﬁed as a genetic back-
ground of cystic ﬁbrosis. CFTR is expressed in diverse tissues including
the kidney, pancreas, intestine, heart, vas deferens, sweat duct and
lungs. CFTRmediates Cl− secretion at the apical membrane of polarized
epithelial cells. Mutations in CFTR result in faulty Cl− transport, which
causes dehydration of secretions with hyperviscous mucus and leads
to chronic airway disease, pancreatic insufﬁciency, intestinal mal-
absorption, and male infertility. CFTR belongs to the ATP-binding cas-
sette (ABC) transporter superfamily, and is the only ion channel
among the thousands of ABC transporter members. CFTR consists of
two membrane-spanning domains, two nucleotide-binding domains,
and a regulatory (R) domain. CFTR is activated through cAMP-
dependent protein kinase (PKA) phosphorylation of the R domain. The
number of CFTR channels in the apical plasmamembrane is determined
by regulation of endocytic retrieval of CFTR from the plasmamembrane
and exocytic insertion of CFTR into the plasma membrane [3,60,61].
Yang et al. clariﬁed the regulation of CFTR by IRBIT [12,39]. IRBIT
binds and activates CFTR in an ectopic expression system in HEK cells.
Deletion of any of the IRBIT domains (PEST, coiled coil, C-terminus 10
amino acids) has no effect on the interaction with CFTR, but completely
disrupts the activation of CFTR by IRBIT. Similarly, mutation of Ser68 of
IRBIT has no effect on the interaction, but disrupts the activation of
CFTR. One potential explanation for these apparent differences between
the interaction and the activation is that another protein is required for
the activation of CFTR by IRBIT. That is, IRBIT, CFTR, and the additional
protein are assembled into a complex, and deletion of either IRBIT do-
main might interfere with recruitment of the additional protein to the
complex that allows activation of CFTR by IRBIT. Thus, the mechanism
of CFTR activation by IRBIT is different from that of NBCe1-B activation.
IRBIT increases open probability of CFTR by reducing the interburst
duration [12]. IRBIT binds to the R domain of CFTR, which has partial
homology with the AID in NBCe1-B. Mutant CFTR lacking the R domain
is not activated by IRBIT [53]. In addition to the direct activation, IRBIT
also regulates the cell surface expression of CFTR. IRBIT antagonizes
the WNK/SPAK kinase pathway by recruiting PP1 to dephosphorylate
CFTR and enhances the cell surface expression of this receptor, as
described above in the NBCe1-B section [39] (Fig. 3A, B). In the mouse
pancreatic duct, siRNA knockdown of IRBIT inhibits CFTR-mediated Cl
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the salivary gland duct, CFTR is synergistically activated through the
combination of low doses of forskolin and carbachol. This synergistic
activation is markedly reduced in the IRBIT knockout mouse. Thus,
IRBIT increases CFTR activity in secretory glands [13]. The regulation
of CFTR by IRBIT might be one of the mechanisms underlying
CFTR activation through Ca2+-mobilizing agonist stimulation [62]. In
contrast, Martins et al. observed no co-immunoprecipitation of IRBIT
and CFTR from two different cell lines (A549 cells and BHK cells)
[63], suggesting that the IRBIT–CFTR interaction might be cell-type
speciﬁc.5.5. Slc26a6
Slc26a6 is a member of the Cl−/HCO3− exchanger family (SLC26
family) expressed in various tissues, including the kidney, heart,
bronchial epithelium, pancreas, prostate, thymus and intestine. In
the pancreas, Slc26a6 localizes apically at the pancreatic duct,
where it functions with CFTR to absorb Cl− and secrete HCO3− into
the lumen [64,65]. The C-terminal tail of Slc26a6 contains a sulfate
transporter and anti-sigma antagonist (STAS) domain, which binds
to the R domain of CFTR and activates CFTR activity. The phosphory-
lation of R domain by PKA enhances the interaction between Slc26a6
and CFTR [66,67].
IRBIT interacts with Slc26a6 through the STAS domain [13,53].
Slc26a6-mediated Cl−/HCO3− exchange activity is increased by over-
expression of IRBIT in HeLa cells. Surface expression of Slc26a6 is
down-regulated by the WNK/SPAK kinase pathway and IRBIT reverses
its effect, in a similarway to its action onNBCe1-B and CFTR. The activity
of Scl26a6 is augmented through a P2Y2 receptor agonist ATP,which ac-
tivates PLC and generates IP3. Inhibition of IP3 production or buffering of
IP3 blocks activation of Slc26a6 through ATP. ATP stimulation increases
the IRBIT–Scl26a6 interaction and reduces the IRBIT–IP3R interaction.
These results indicate that IP3, produced by ATP stimulation, dissociates
IRBIT from IP3R, and the released IRBIT binds to Slc26a6 to facilitate the
surface expression of this exchanger [13] (Fig. 3B). In the mouse pan-
creatic ducts, siRNA knockdown of IRBIT inhibits Cl−/HCO3− exchange
activity of Slc26a6 [12]. Moreover, the Scl26a6 activity in parotid ducts
is signiﬁcantly reduced in the IRBIT knockout mouse to the same extent
as that in the Slc26a6 knockout mouse. Thus, IRBIT increases luminal
HCO3− secretion by stimulating surface expression of Scl26a6 and CFTR
in secretory epithelial cells [13].5.6. Fip1
Proteomic analysis of IRBIT-associated proteins in 293EBNA cells
identiﬁed proteins involved in mRNA processing, including CPSF160,
CPSF73, CPSF30, and Fip1, all of which are members of the cleavage
and polyadenylation speciﬁcity factor (CPSF) complex [32]. CPSF plays
roles in the 3′ processing of mRNA precursors, cleavage and poly-
adenylation. CPSF cleaves the 3′ extremity of pre-mRNAs and is also re-
quired for the efﬁcient and speciﬁc polyadenylation of pre-mRNAs
through poly(A) polymerase (PAP) [68]. The primary target for IRBIT
in the CPSF complex is the Fip1 subunit. Except Long-IRBIT, Fip1 is the
only known IRBIT-interacting protein that is not an ion channel/
transporter. Fip1 is mainly localized in the nucleus, but is partially
redistributed to the cytoplasm by overexpression of IRBIT. IRBIT forms
a ternary complex with Fip1 and PAP, and inhibits the polyadenylation
activity of PAP in vitro in a phosphorylation-dependent manner. IRBIT
might modulate the polyadenylation state of speciﬁc mRNAs [32]. In
some cancer cells, IRBIT extensively localizes in the nucleus [44], raising
the possibility that IRBIT has additional functions other than the regula-
tion of ion channels/transporters. Fip1 might be a potential target
molecule of nuclear IRBIT.6. Binding determinants in target proteins
IRBIT interacts with IP3R1 by recognizing positively charged amino
acids lyingwithin the IP3 binding pocket of IP3R1 [9]. Howdoes IRBIT in-
teract with ion transporters with no sequence homologywith IP3R? The
N-terminal 62 amino acids of NBCe1-B comprise the IRBIT binding,
which overlapswith theAID [10,38]. TheNa+-coupledHCO3− transport-
er superfamily has a conserved cluster of positively charged amino acids
(residues 40–62 in NBCe1-B) [53]. Recently, Hong et al. revealed that an
NBCe1-B mutant lacking residues 40–62 does not bind to IRBIT and is
fully active due to the removal of autoinhibition. Among residues
40–62, three arginine residues, Arg42, Arg43, and Arg44, are critical.
The triple mutation of these arginines (R42/43/44A) nearly completely
eliminates the IRBIT interaction, and themutant NBCe1-B is not activat-
ed by IRBIT. These authors also showed that NBCe1-B is directly activat-
ed by PIP2. PIP2 and IRBIT activate NBCe1-B to the same extent, and this
activation is nonadditive. Importantly, the R42/43/44Amutant is not ac-
tivated by PIP2. Therefore, IRBIT and PIP2 bind to the same positively
charged arginines within the AID [53]. This observation is consistent
with the observations that IRBIT and IP3, a hydrolytic product of PIP2
through PLC, bind to the same site in the IP3 binding pocket of IP3R1
[9]. Negatively charged phospho-serines in the serine-rich region of
IRBIT are assumed to interact with positively charged clusters on the
target proteins through electrostatic interactions. Positively charged
amino acids are clustered in the primary sequence of NBCe1-B, whereas
these residues are widely distributed throughout the primary sequence
of the IP3-binding domain of IP3R1 and are adjacent in the three-
dimensional structure of this receptor [45,46]. Hong et al. also identiﬁed
the binding determinants in NBCn1-A (Arg56, Arg57 and Arg58), CFTR
(the R domain), and Scl26a6 (the STAS domain). The R domain of
CFTR and the STAS domain of Slc26a6 have weak but signiﬁcant homol-
ogy with the AID of NBCe1-B [53]. The IRBIT binding site in NHE3 is lo-
cated within residues 592–696 [11], which contains positively charged
clusters. The IRBIT binding site in Fip1 is located in the C-terminal
arginine-rich domain [32]. Therefore, clusters of positively charged
amino acids are assumed to be critical determinants of binding in target
proteins of IRBIT.
7. Physiological and pathological roles
7.1. Epithelial ﬂuid and HCO3
− secretion in exocrine glands
Epithelial ﬂuid and HCO3− secretion in exocrine glands, such as the
pancreatic duct, requires HCO3− entry at the basolateral membrane
(BLM) and HCO3− exit at the luminal membrane (LM). Tight coordina-
tion of HCO3− entry and HCO3− exit increases the ﬁdelity of the secretory
process. Basolateral HCO3− entry is mediated through the N+/HCO3−
cotransporter NBCe1-B, and luminal HCO3− exit is mediated through
the concerted activities of the Cl− channel CFTR and the Cl−/HCO3− ex-
changer Slc26a6 [59]. IRBIT plays important roles in the coordinated
regulation of these ion transporters/channels at both the BLM and LM.
Silencing of IRBIT in the pancreatic duct by siRNA strongly inhibits
ﬂuid secretion [12,39]. IRBIT increases ﬂuid secretion through the direct
activation of NBCe1-B at the BLM and CFTR at the LM [10,12] and
through antagonizing the WNK/SPAK kinase pathway to increase the
surface expression of NBCe1-B, CFTR, and Slc26a6 [13,39,53].
We recently generated an IRBIT knockout mouse. Pancreatic ducts
in primary culture secrete ﬂuid and electrolytes in response to the
cAMP-generating agonist, secretin. A low concentration of secretin or
the IP3-generating agonist carbachol induces minimal secretion; how-
ever, co-stimulation with low concentrations of secretin and carbachol
synergistically induces robust secretion. The deletion of IRBIT in mice
eliminates ﬂuid secretion through the synergistic stimulation of
cAMP- and IP3-generating agonists from the pancreatic ducts. The
IRBIT knockout mice also showed a decrease in the Slc26a6 activity in
parotid ducts and CFTR activity in salivary gland ducts. The molecular
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volve 1) decreased afﬁnity of the IRBIT–IP3R interaction by PKA phos-
phorylation of IP3R, 2) dissociation of IRBIT from IP3R by IP3, and 3)
binding of the released IRBIT to NBCe1-B, CFTR and Slc26a6, and aug-
mentation of the activities of these proteins [13]. Thus, IRBIT functions
as a switch that triggers and regulates the ﬂuid and HCO3− secretory
state in secretory epithelia [40,58,59].
7.2. Zebraﬁsh embryonic development
The regulation of IP3R by IRBIT plays a key role in embryonic devel-
opment in zebraﬁsh. Cooper et al. found that IRBIT expressionmarkedly
increases from the sphere stage to the 25-somite stage in zebraﬁsh
development. Suppression of IRBIT using morpholino antisense oligo-
nucleotides induces a ventralized morphology, with abnormal devel-
oped and necrotic brain structures and expanded ventral tail ﬁn
tissue. Conversely, injection of IRBIT mRNA into zebraﬁsh embryo
induces dorsalizedmorphologies [19], which is consistent with ﬁndings
that the pharmacological depletion of intracellular Ca2+ stores or the
suppression of IP3R through the injection of the anti-IP3R antibody
induced dorsalization in zebraﬁsh or Xenopus [69,70]. Ashworth et al.
demonstrated that the pharmacological inhibition of IP3R, depletion of
Ca2+ stores, or injection of recombinant IRBIT disrupts early blastula
formation in zebraﬁsh [71]. These observations indicate that IRBIT regu-
lates embryo development through the regulation of Ca2+ signaling in
zebraﬁsh.
7.3. Tumor
Jeong et al. studied IRBIT expression in ovarian cancer [44]. The lay-
ing hen is the only animal that spontaneously develops tumors from
ovarian surface epithelium. Expression of IRBIT markedly increases in
the glandular epithelia of cancerous ovaries compared with the normal
ovaries of hens. Demethylation in the 5′ promoter region of the IRBIT
gene partly accounts for the up-regulation of IRBIT in cancerous cells.
IRBIT is highly expressed in nucleus of chicken ovarian cancer cells,
but detectable only at lower levels in the cytoplasm of normal ovarian
epithelial cells. Similarly, in the human ovarian cancer cell line,
OVCAR-3, IRBIT is localized primarily in the nucleus [44]. The function
of nuclear IRBIT is unclear, but Fip1 might be a potential target [32]. In
contrast to chicken, IRBIT expression is decreased in human ovarian ep-
ithelial cancer. High expression of IRBIT is a favorable factor for overall
responses and progression-free survival. These results suggest a para-
doxical function of IRBIT in ovarian carcinogenesis; IRBIT expression is
associated with ovarian carcinogenesis as an oncogene in chickens,
whereas IRBIT functions as a tumor suppressor in human epithelial
ovarian cancer [44]. Themolecularmechanismbywhich IRBIT regulates
oncogenesis remains unknown. However, IRBIT expression is reported
to be down-regulated in response to chemotherapeutic drugs in a
human malignant melanoma cell line [72].
Arai et al. identiﬁed a novel gene fusion of ﬁbroblast growth factor
receptor 2 (FGFR2) and AHCYL1 (a gene encoding IRBIT) through geno-
mic rearrangement in cholangiocarcinoma patients [73]. The in-frame
fusion gene encodes a chimeric protein of FGFR2 and IRBIT (residues
41–530). NIH3T3 cells overexpressing the FGFR2-IRBIT fusion protein
show anchorage-independent colony formation in soft agar. Subcutane-
ous transplantation of these clones into immunodeﬁcient mice results
in the formation of tumors, whereas cells expressing the fusion protein
with kinase-dead mutations do not exhibit tumor formation. The
FGFR2-IRBIT expressing cells show constitutive tyrosine phosphoryla-
tion in the activation loop of the FGFR2 kinase domain and the hyper-
activation of MAPK [73]. Because FGFR2 dimerization induced by
ligand binding initiates a cascade of intracellular signals [74], the
multimerization of FGFR2-IRBIT via the AHCY domain of IRBIT might
induce the ligand-independent constitutive activation of FGFR2-IRBIT,
resulting in tumorigenesis.8. Conclusions
IRBIT, which evolved from a metabolic enzyme by acquiring a
unique serine-rich region, is assumed to regulate both ion channels
(IP3R and CFTR) and ion transporters (NBCe1-B, NHE3 and Slc26a6), de-
pending on its phosphorylation status and on tissues or cell type
expression. Fig. 3 shows models of IRBIT functions. At resting state, or
when the IP3 concentration near IP3R is lowdue to theweak stimulation
or spatial segregation of the sites of IP3 production and locations of IP3R,
phosphorylated IRBIT interacts with the IP3-binding domain of IP3R and
suppresses the activation of IP3R as an inhibitory gatekeeper. At this
state, IP3R sequesters active (that is, phosphorylated) IRBIT from trans-
porters (Fig. 3A andB, left).When agonist stimulation results in the pro-
duction of a high concentration of IP3, IP3 displaces IRBIT and activates
IP3R. Active IRBIT released from IP3R binds to the AID of NBCe1-B or
the R domain of CFTR and increases the activity of these proteins
(Fig. 3A, right). In addition to direct activation, IRBIT recruits PP1 to
transporters/channels (NBCe1-B, CFTR, and Scl26a6) on intracellular
vesicles to antagonize the WNK/SPAK kinase pathway and induces
their surface expression (Fig. 3B, right). After insertion of NBCe1-B or
CFTR into the plasmamembrane, IRBIT remains bound to them and aug-
ments their activities (Fig. 3A, right). In the case of NHE3, the intracellu-
lar Ca2+ increase activates CaMKII, and IRBIT is activated through
phosphorylation downstream of CaMKII. Active IRBIT interacts with
the C-terminal domain of NHE3 and stimulates its surface expression.
The binding of active IRBIT to IP3R might be one mechanism of negative
feedback regulation of IP3R (Fig. 3C).
There are many unsolved questions. First, the physiological roles of
IRBIT in systems other than secretion, particularly in the central nervous
system,where IRBIT is highly expressed, remain largely unknown. Anal-
ysis of the recently generated IRBIT knockout mouse [13] is expected to
reveal the diverse roles of IRBIT in vivo. Second, kinases that phosphor-
ylate Ser68 in IRBIT in vivo remain obscure. In addition, there might be
additional critical phosphorylation sites by other kinases. The different
phosphorylation patterns of multiple phosphorylation sites might
determine the target speciﬁcity of IRBIT. Third, nuclear localization of
IRBIT in ovarian cancer cells [44] suggests functions other than regula-
tion of ion channels/transporters.Whether IRBIT regulates gene expres-
sion by interacting with Fip1, and whether nuclear IRBIT is involved in
tumorigenesis are interesting questions. Fourth, the function of Long-
IRBIT remains unexplored, except that the LISN domain inhibits the
interaction with IP3R and Long-IRBIT forms heteromultimer with IRBIT
[14]. Undoubtedly, the LISN domain is the key to understanding the
functions of Long-IRBIT. Further studies are anticipated to reveal the
physiological and pathological functions of this intriguing regulator of
ion channels and ion transporters.Acknowledgements
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